Breaking down the boundaries of laser vision correction surgery, the Advanced CustomVue procedure has the broadest range of wavefront guided approvals, with an unprecedented level of precision and accuracy. The procedure leverages Iris Registration, Fourier algorithms, VSS™ and VRR™ technologies, and 3D ActiveTrak™ to ensure precise ablation. Now, more than 94 percent of the population in the U.S. and 99.75 percent outside the U.S. are potentially eligible to benefit from laser vision correction surgery.*

*Market Scope Data, U.S. Vision Population, 21 years of age or older, 2005

For consumer information on iLASIK™ please visit

http://www.ilasik.com

Only the Advanced CustomVue procedure with the proprietary AMO Fourier algorithm offers the highest resolution of wavefront error. Hartmann-Shack technology and Fourier analysis enable treatment based on approximately 240 data points across a patient's pupil. Access to precise data enables the treatment of both higher- and lower-order aberrations with extremely high success rates, delivering a potentially superior vision correction alternative to glasses and contact lenses for eligible vision correction candidates.

In another industry first, AMO's Advanced CustomVue ™ procedure is now the only FDA-Approved Wavefront-guided laser vision correction treatment for the correction of both near and distance vision of presbyopic patients.
The Advanced CustomVue procedure provides a full range of treatments for patients who have all forms of astigmatism, whether associated with nearsightedness, farsightedness or mixed astigmatism. The Advanced CustomVue procedure has the broadest FDA-approved, custom wavefront-guided treatments available today for individuals with myopia and hyperopia with or without astigmatism. This procedure has been approved for treating:

• Myopia — up to 11.0 diopters of correction, with or without astigmatism up to -3 diopters
• Hyperopia — up to 3 diopters of correction with or without astigmatism up to +2 Diopters
• Mixed astigmatism up to 5 diopters
• Monovision — retention of up to -2.0 D of myopia in the non dominant eye of patients with myopia up to -6.0 D and astigmatism up to -3.0 D

Results from multi-center clinical studies demonstrate that the Advanced CustomVue procedure enables excellent outcomes for the broadest range of FDA-approved wavefront-guided treatments:

• Low to Moderate Myopia: In clinical studies, 100 percent of patients treated for moderate myopia could pass a driving test without glasses or contact lenses, and 98 percent had 20/20 vision or better one year after treatment.
• Hyperopia: Four times as many participants were very satisfied with their vision after the procedure, compared to their vision before the procedure with glasses and contact lenses.
• Mixed Astigmatism: Three months after the Advanced CustomVue procedure, 100 percent of eyes treated for mixed astigmatism showed either a decrease or a change of less than or equal to 0.1 microns of higher-order RMS.
• High Myopia: Only 2.2 percent of eyes in the high myopia clinical trial required re-treatment. The High Myopia study was the first to utilize Fourier algorithms to construct treatment plans.
• Monovision: 12 months after the multi-center clinical trial, 98% of patients expressed satisfaction with the results, and if given the choice, would elect to have the Advanced CustomVue Monovision procedure again.

Clearer Night Vision: For all indications submitted to the FDA, satisfaction with night vision improved after the CustomVue procedure.

The Advanced CustomVue procedure consists of the following four steps:

1. Acquire: Data on the patient's wavefront error is collected with the AMO WaveScan WaveFront™ System.
2. Design: A customized treatment is designed using the data collected on the unique characteristics of the patient's eye with unique proprietary algorithms.
3. Align: The treatment is aligned to the patient's eye using Iris Registration technology, which links diagnostic information to the treatment delivered during the Advanced CustomVue procedure.
4. Deliver: Using VSS™ and VRR™ technologies ensures the intricate shapes reconstructed by the Fourier wavefront algorithm are precisely ablated by the STAR S4 IR Excimer Laser System.